7MM myasthenia gravis market to be valued at $10.3b by 2034

Its growth is attributed to the anticipated launch of seven late-stage pipeline therapies.

The myasthenia gravis (MG) market across seven major markets (7MM) is projected to reach $10.3b by 2034 at a compound annual growth rate of 5.3%, according to GlobalData.

The sector’s expansion is attributed to the rising number of diagnosed cases and the anticipated launch of seven late-stage pipeline therapies.

In addition, six of the late-stage pipeline agents are expected to be used across multiple antibody subtypes.

However, continued generic erosion and the entry of biosimilars will be a significant growth barrier, particularly in the US, according to Jos Opdenakker, Neurology Analyst at GlobalData.

“Although the impending entry of numerous biosimilar products will act as a major barrier, late-stage pipeline products have the potential to generate significant growth in the MG market,” Opdenakker added.

7MM = US, France, Germany, Italy, Spain, UK, and Japan.